Aktie A0X789 IRONWOOD PHARMACEUTICALS, INC.
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren

Andere Sprachen Ironwood Pharmaceuticals, Inc.

Aktien

A0X789

US46333X1081

IRWD

Markt geschlossen - Nasdaq
Andere Börsenplätze
 22:00:00 28.05.2024 		% 5 Tage % 1. Jan.
5,88 USD -1,18 % Intraday Chart für Ironwood Pharmaceuticals, Inc. -13,27 % -48,60 %
22.05. Ironwood Pharmaceuticals Insider verkaufte Aktien im Wert von $436.136, laut einer aktuellen SEC Einreichung MT
21.05. Ironwood Pharmaceuticals, Inc. präsentiert auf der Digestive Disease Week 2024 aktuelle Daten aus der klinischen Phase-III-Studie STARS (Pivotal Phase III) CI

Andere Sprachen

Suchen
Ergebnisse ansehen
Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!
100% kostenlose Registrierung
Ironwood Pharmaceuticals Insider Sold Shares Worth $436,136, According to a Recent SEC Filing
Ironwood Late-Breaker Oral Presentation at Digestive Disease Week Reinforces Potential of Once-Weekly Apraglutide for Adults with Short Bowel Syndrome with Intestinal Failure
Ironwood Pharmaceuticals : Late-Breaker Oral Presentation at Digestive Disease Week®
Ironwood Late-Breaker Oral Presentation at Digestive Disease Week® Reinforces Potential of Once-Weekly Apraglutide for Adults with Short Bowel Syndrome with Intestinal Failure (SBS-IF)
Ironwood Pharmaceuticals, Inc. Presents Late-Breaking Data During the 2024 Digestive Disease Week Meeting from Its Pivotal Phase III Clinical Trial, STARS
Sector Update: Health Care Stocks Higher Late Afternoon
Sector Update: Health Care Stocks Gain in Thursday Afternoon Trading
Sector Update: Health Care
Ironwood Pharmaceuticals' Shares Fall After Q1 Swings to a Non-GAAP Loss, Revenue Declines; 2024 Revenue Guidance Cut
Ironwood Pharmaceuticals : 1Q 2024 Investor Update
(IRWD) IRONWOOD PHARMACEUTICALS Expects Fiscal Year 2024 Revenue Range $405M - $425M
Earnings Flash (IRWD) IRONWOOD PHARMACEUTICALS Reports Q1 Revenue $74.9M
Ironwood: Q1 Earnings Snapshot
Ironwood Pharmaceuticals, Inc. Revised Earnings Guidance for Its Fiscal Year 2024
Ironwood Pharmaceuticals Reports First Quarter 2024 Results
Ironwood Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
Ironwood Pharmaceuticals to Participate in The Citizens JMP Life Sciences Conference
Ironwood Pharmaceuticals to Present New Data on Once-Weekly Apraglutide in Short Bowel Syndrome with Intestinal Failure (SBS-IF) at Digestive Disease Week® 2024
Ironwood Pharmaceuticals to Host First Quarter 2024 Investor Update Call
Ironwood Pharmaceuticals : ESG/Responsibility
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. A0X789 Aktie
  4. Nachrichten Ironwood Pharmaceuticals, Inc.
  5. Andere Sprachen